Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 8, 2025Frontiers in OncologyOpen Access

Multiplexed immune profiling and 3D co-culture assays to assess the individual checkpoint therapy response in head and neck squamous cell carcinoma

View Full Paper
Ask AI
Bookmark
Share

Authors

VSVerena SchweihoferDSDaniela SchulzRBRaquel Blazquez

Discussion

Loading...

Member takes

Overview

This research demonstrates immune and tumor profiles in head and neck squamous cell carcinoma, suggesting predictive biomarkers for checkpoint therapy.

Key Points

  • Significant changes in immune cell profiles were observed in patients with head and neck squamous cell carcinoma.
  • The study found frequent co-expression of PD-1 and TIM-3 on CD8 + tumor-infiltrating T cells.
  • Employing a 3D co-culture model revealed enhanced responses to atezolizumab treatment in tumor–immune interactions.
  • The findings highlight a potential method for predicting immune checkpoint inhibitor response, necessitating further validation.

Cite This Study

Schweihofer et al. (2025) studied this question.

synapsesocial.com/papers/68af2b63cf1dd9ea359e4a2ehttps://doi.org/10.3389/fonc.2025.1622008
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Inflammation and limited adaptive immunity predict worse outcomes on immunotherapy in head and neck cancer2025
  2. 2Single-Cell Transcriptomics Identifies Novel Prognostic Signatures in HNSCC Immunotherapy Response.2025
  3. 3Longitudinal liquid biopsy identifies an early predictive biomarker of immune checkpoint blockade response in head and neck squamous cell carcinoma2025
  4. 4Application of comprehensive multi-omic immune profiling strategy achieves superior checkpoint immunotherapy response prediction in lung cancer 35072025
  5. 5Co-Stimulatory and Immune Checkpoint Molecule Expression on Peripheral Immune Cells Differs Age Dependently Between Healthy Donors and Patients with Head and Neck Squamous Cell Carcinoma2025